Impact of extrafine formulation single-inhaler triple therapy on treatment adherence and patient satisfaction in adult asthma – results from the TriMaximize UK study (ID 599)
Chiesi Ltd
Abstract
Background: The efficacy of an extrafine formulation single-inhaler triple therapy (SITT) beclometasone/formoterol/glycopyrronium (BDP/FF/G) in adults with uncontrolled moderate-to-severe asthma has been demonstrated in randomised controlled trials (RCTs),1 yet real-world evidence is limited.
Methods: TriMaximize is a prospective, non-interventional, multicentre study describing patient-characteristics and therapy pathways in patients with moderate-to-severe asthma, treated with BDP/FF/G.
This UK cohort data (NCT04902573) describes the treatment impact with BDP/FF/G on inhaler adherence, assessed by the Test of Adherence to Inhalers (TAI) and patient satisfaction after switching from a previous therapy.
Results: Of 166 patients enrolled across 20 UK centres, 147 are included (19 excluded as inclusion criteria not fulfilled or missing core baseline data) in the full analysis set. Patients are consenting adults diagnosed with asthma, with/without concomitant COPD. Prior to enrolment, 106 (72.1%) patients were treated with ICS/LABA or 41 (27.9%) with ICS/LABA/LAMA (both fixed or free combination). Main reasons for therapy switch to BDP/FF/G were poor control of symptoms under previous therapy (74.1%) and disease progression (17.7%).
The mean baseline TAI score was 48.0 points with 56.6% patients displaying good adherence, increasing to 49.2 points after twelve-months treatment with BDP/FF/G (p=0.0062) - Figure 1. Overall, 78.8% of patients were categorised as TAI responders, achieving a higher adherence category or maintaining good adherence after twelve-months. A total of 94.8% (n=73) patients reported being very satisfied/satisfied with treatment and 100.0% (n=75) were very satisfied/satisfied with inhaler handling.
Conclusion: A significant improvement in treatment adherence was observed over a twelve-month period with SITT BDP/FF/G, with treatment satisfaction reported by patients.
Reference
1. Virchow JC et al. Lancet 2019; 394(10210):1737-49
Funding: This research has been funded by Chiesi Ltd.
Conflicts of interest: RR has received fees for conducting the study. JR and AR are employees of Chiesi Ltd.
The conference has been instigated and organised by PCRS. We are grateful to sponsors and exhibitors who have contributed funding towards this event in return for exhibition space. Neither sponsors or exhibitors have had any input into the agenda or the selection of speakers with the exception of any sponsored satellite symposia which are clearly indicated. View the full list of sponsors.
The conference social programme - dinner, drinks and disco - is not covered by sponsorship or exhibition fees.